Cargando…

Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy

INTRODUCTION: Before dapoxetine was approved for the treatment of lifelong premature ejaculation (LPE) in China, daily dosing with off-label sertraline was common. AIM: To investigate the efficacy of dapoxetine in the treatment of patients with LPE as an alternative to sertraline therapy. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Guoxiong, Yin, Yinghao, Zhang, Lei, He, Dalin, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847844/
https://www.ncbi.nlm.nih.gov/pubmed/34968812
http://dx.doi.org/10.1016/j.esxm.2021.100473
_version_ 1784652133207900160
author Liu, Guoxiong
Yin, Yinghao
Zhang, Lei
He, Dalin
Yang, Lin
author_facet Liu, Guoxiong
Yin, Yinghao
Zhang, Lei
He, Dalin
Yang, Lin
author_sort Liu, Guoxiong
collection PubMed
description INTRODUCTION: Before dapoxetine was approved for the treatment of lifelong premature ejaculation (LPE) in China, daily dosing with off-label sertraline was common. AIM: To investigate the efficacy of dapoxetine in the treatment of patients with LPE as an alternative to sertraline therapy. METHODS: This prospective study included LPE patients who previously attempted treatment with sertraline and who agree to receive dapoxetine therapy in our hospital from January 2020 to March 2021. Patients who received any PE therapy in the two months prior to the dapoxetine therapy were excluded. All patients received dapoxetine 30 mg (taken 1–3 hours before sexual intercourse) for 12 weeks, and they were not taking sertraline during the trial. MAIN OUTCOME MEASURE: Data on their intravaginal ejaculatory latency time and premature ejaculation profile were recorded before and after the dapoxetine treatment. Clinical Global Impression of Change scores and data on Treatment-Emergent adverse events were collected after treatment. RESULTS: A total of 144 patients with LPE completed this study; including 64 patients who reported that previous sertraline treatment was satisfactory (group A) and 80 patients for whom previous sertraline therapy was unsatisfactory in treating PE (group B). Both groups experienced significantly increased intravaginal ejaculatory latency time. Dapoxetine therapy was reported satisfactory by 67.5% of patients with LPE in whom sertraline therapy unsatisfactory according to their Clinical Global Impression of Change score, which was not different from those who reported this result in group A (62.5%). Similar outcomes were also reported for premature ejaculation profile and treatment-emergent adverse events. CONCLUSION: : Although both dapoxetine and sertraline are selective serotonin re-uptake inhibitors, dapoxetine therapy is satisfactory in 67.5% of patients with LPE in whom sertraline treatment unsatisfactory, and the effect of dapoxetine was independent of the effect of sertraline. Liu G, Yin Y, Zhang L. et al., Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy. Sex Med 2021;10:100473.
format Online
Article
Text
id pubmed-8847844
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88478442022-02-22 Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy Liu, Guoxiong Yin, Yinghao Zhang, Lei He, Dalin Yang, Lin Sex Med Original Research INTRODUCTION: Before dapoxetine was approved for the treatment of lifelong premature ejaculation (LPE) in China, daily dosing with off-label sertraline was common. AIM: To investigate the efficacy of dapoxetine in the treatment of patients with LPE as an alternative to sertraline therapy. METHODS: This prospective study included LPE patients who previously attempted treatment with sertraline and who agree to receive dapoxetine therapy in our hospital from January 2020 to March 2021. Patients who received any PE therapy in the two months prior to the dapoxetine therapy were excluded. All patients received dapoxetine 30 mg (taken 1–3 hours before sexual intercourse) for 12 weeks, and they were not taking sertraline during the trial. MAIN OUTCOME MEASURE: Data on their intravaginal ejaculatory latency time and premature ejaculation profile were recorded before and after the dapoxetine treatment. Clinical Global Impression of Change scores and data on Treatment-Emergent adverse events were collected after treatment. RESULTS: A total of 144 patients with LPE completed this study; including 64 patients who reported that previous sertraline treatment was satisfactory (group A) and 80 patients for whom previous sertraline therapy was unsatisfactory in treating PE (group B). Both groups experienced significantly increased intravaginal ejaculatory latency time. Dapoxetine therapy was reported satisfactory by 67.5% of patients with LPE in whom sertraline therapy unsatisfactory according to their Clinical Global Impression of Change score, which was not different from those who reported this result in group A (62.5%). Similar outcomes were also reported for premature ejaculation profile and treatment-emergent adverse events. CONCLUSION: : Although both dapoxetine and sertraline are selective serotonin re-uptake inhibitors, dapoxetine therapy is satisfactory in 67.5% of patients with LPE in whom sertraline treatment unsatisfactory, and the effect of dapoxetine was independent of the effect of sertraline. Liu G, Yin Y, Zhang L. et al., Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy. Sex Med 2021;10:100473. Elsevier 2021-12-27 /pmc/articles/PMC8847844/ /pubmed/34968812 http://dx.doi.org/10.1016/j.esxm.2021.100473 Text en Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research
Liu, Guoxiong
Yin, Yinghao
Zhang, Lei
He, Dalin
Yang, Lin
Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy
title Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy
title_full Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy
title_fullStr Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy
title_full_unstemmed Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy
title_short Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy
title_sort efficacy of dapoxetine in the treatment of patients with lifelong premature ejaculation as an alternative to sertraline therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847844/
https://www.ncbi.nlm.nih.gov/pubmed/34968812
http://dx.doi.org/10.1016/j.esxm.2021.100473
work_keys_str_mv AT liuguoxiong efficacyofdapoxetineinthetreatmentofpatientswithlifelongprematureejaculationasanalternativetosertralinetherapy
AT yinyinghao efficacyofdapoxetineinthetreatmentofpatientswithlifelongprematureejaculationasanalternativetosertralinetherapy
AT zhanglei efficacyofdapoxetineinthetreatmentofpatientswithlifelongprematureejaculationasanalternativetosertralinetherapy
AT hedalin efficacyofdapoxetineinthetreatmentofpatientswithlifelongprematureejaculationasanalternativetosertralinetherapy
AT yanglin efficacyofdapoxetineinthetreatmentofpatientswithlifelongprematureejaculationasanalternativetosertralinetherapy